Table 2.

Hazard ratio over time in key studies

	Checkmate 214[16,43]
	Favorable risk		Intermediate/poor risk		ITT
Median follow-up	PFS (HR)	OS (HR)	PFS (HR)	OS (HR)	PFS (HR)	OS (HR)
25.2 mo	2.18 (1.29–3.68) (P <0.001)	1.45 (0.51–4.12) (P =0.27)	0.82 (0.64–1.05) (P = 0.03)	0.63 (0.44–0.89) (P < 0.001)	0.98 (0.79–1.23) (P = 0.85)	0.68 (0.49–0.95) (P < 0.001)
32.4 mo	1.23 (0.9–1.69) (P = 0.19)	1.22 (0.73–2.04) (P = 0.44)	0.77 (0.65–0.90) (P < 0.01)	0.66 (0.54–0.80) (P < 0.0001)	0.85 (0.73–0.98) (P = 0.03)	0.71 (0.59–0.86) (P < 0.01)
43.6 mo	1.65 (1.16–2.35) (0.0049)	1.19 (0.77–1.85) (P = 0.43)	0.75 (0.62–0.90) (P = 0.015)	0.66 (0.55–0.80) (P < 0.0001)	0.88 (0.75–1.04) (P = 0.126)	0.72 (0.61–0.86) (P = 0.0002)
	Keynote 426 [59,60]
	Favorable risk		Intermediate (int)/poor risk		ITT
Median follow-up	PFS (HR)	OS (HR)	PFS (HR)	OS (HR)	PFS (HR)	OS (HR)
12.8 mo	0.81 (0.53–1.24)	0.64 (0.24–1.68)	0.70 (0.54–0.91) (int) 0.58 (0.35–0.94) (poor)	0.53 (0.35–0.82) (int) 0.43 (0.23–0.81) (poor)	0.69 (0.57–0.84) P < 0.001	0.53 (0.38–0.74) P < 0.001
30.6 mo	0.79 (0.57–1.09) (P = 0.078)	1.06 (0.6–1.86) P = 0.58	0.69 (0.56–0.84) (P = 0.0002)	0.63 (0.5–0.81) (P = 0.0001)	0.71 (0.60–0.84) (P < 0.0001)	0.68 (0.55–0.85) P = 0.0003
	Javelin Renal 101 [61,62]
	PD-L1+		ITT
Median follow-up	PFS (HR)	OS (HR)	PFS (HR)	OS (HR)
11.6 mo	0.61 (0.47–0.79) P < 0.001	0.82 (0.53–1.28) P = 0.38	0.69 (0.56–0.84) (P < 0.01)	0.69 (0.56–0.84) (P < 0.001)
19.2 mo	0.62 (0.49–0.77) (P = 0.0001)	0.83 (0.59–1.15) (P = 0.13)	0.69 (0.57–0.82) (P < 0.0001)	0.80 (0.61–1.02) (P = 0.03)

HR: Hazard ratio; PFS: progression free survival; ITT: intention to treat; OS: overall survival; PD-L1: programmed cell death ligand 1; mo: month(s).